Abstract
S-100 protein, described initially by Moore, constitutes a large family of at least 20 proteins with calcium binding ability. It is found as homo- or hetero-dimers of two different subunits (A and B). Types S-100AB and S-100BB are described as S-100B protein and are shown to be highly specific for nervous tissue. It is present in the cytosol of glial and Schwann cells, and also in adipocytes and chondrocytes, although in very low concentrations in the latter two. The role of protein S-100B is not yet fully understood. It is suggested that it has intracellular and extracellular neurotropic as well as neurotoxic function. At nanomolar levels, S-100B stimulates neurite outgrowth and enhances survival of neurons. However, at micromolar levels it stimulates the expression of inflammatory cytokines and induces apoptosis. Recently, serum S-100B protein has been proved to be an attractive surrogate marker of primary severe brain injury and secondary insults. It can be measured in the arterial and venous serum; it is not affected by haemolysis and remains stable for several hours without the need for immediate analysis. Its short half-life makes measurements crucial in the emergency and intensive care settings. This review summarises published findings on S-100B regarding its role as a serum biochemical marker of brain injury, i.e., after severe, moderate or mild neuro-trauma, subarachnoid haemorrhage, thrombo-embolic stroke, cerebral ischaemia and brain tumours, as well as extracranial trauma, neurodegenerative and psychiatric disorders.
Keywords: S-100B protein, brain injury, neurotrauma, TBI, stroke, ischaemia, subarachnoid haemorrhage, brain tumours
Current Medicinal Chemistry
Title: Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Volume: 13 Issue: 30
Author(s): S. Korfias, G. Stranjalis, A. Papadimitriou, C. Psachoulia, G. Daskalakis, A. Antsaklis and D. E. Sakas
Affiliation:
Keywords: S-100B protein, brain injury, neurotrauma, TBI, stroke, ischaemia, subarachnoid haemorrhage, brain tumours
Abstract: S-100 protein, described initially by Moore, constitutes a large family of at least 20 proteins with calcium binding ability. It is found as homo- or hetero-dimers of two different subunits (A and B). Types S-100AB and S-100BB are described as S-100B protein and are shown to be highly specific for nervous tissue. It is present in the cytosol of glial and Schwann cells, and also in adipocytes and chondrocytes, although in very low concentrations in the latter two. The role of protein S-100B is not yet fully understood. It is suggested that it has intracellular and extracellular neurotropic as well as neurotoxic function. At nanomolar levels, S-100B stimulates neurite outgrowth and enhances survival of neurons. However, at micromolar levels it stimulates the expression of inflammatory cytokines and induces apoptosis. Recently, serum S-100B protein has been proved to be an attractive surrogate marker of primary severe brain injury and secondary insults. It can be measured in the arterial and venous serum; it is not affected by haemolysis and remains stable for several hours without the need for immediate analysis. Its short half-life makes measurements crucial in the emergency and intensive care settings. This review summarises published findings on S-100B regarding its role as a serum biochemical marker of brain injury, i.e., after severe, moderate or mild neuro-trauma, subarachnoid haemorrhage, thrombo-embolic stroke, cerebral ischaemia and brain tumours, as well as extracranial trauma, neurodegenerative and psychiatric disorders.
Export Options
About this article
Cite this article as:
Korfias S., Stranjalis G., Papadimitriou A., Psachoulia C., Daskalakis G., Antsaklis A. and Sakas E. D., Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts, Current Medicinal Chemistry 2006; 13 (30) . https://dx.doi.org/10.2174/092986706779026129
DOI https://dx.doi.org/10.2174/092986706779026129 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytotoxicity and Anti-inflammatory Activity of Flavonoid Derivatives Targeting NF-kappaB
Recent Patents on Inflammation & Allergy Drug Discovery Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued) Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Colloidal and Pharmacological Activity of Albumin in Clinical Fluid Management:Recent Developments
Current Drug Therapy Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review
Current Neuropharmacology The Rabbit Syndrome: State of the Art
Current Clinical Pharmacology Differentiation of High-grade Gliomas from Brain Metastases Using Tissue Similarity Maps (TSMs) Based Relative Cerebral Blood Volume Values
Current Medical Imaging Neuroprotective Therapy for HIV Dementia
Current HIV Research Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery